Literature DB >> 25306183

Words of wisdom. Re: Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Hannelore V Heemers1, James L Mohler2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25306183      PMCID： PMC4331016          DOI： 10.1016/j.eururo.2014.06.032

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  3 in total

Review 1.  Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.

Authors:  Deborah Mukherji; Aurelius Omlin; Carmel Pezaro; Ali Shamseddine; Johann de Bono
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 2.  Minireview: Androgen metabolism in castration-resistant prostate cancer.

Authors:  Nima Sharifi
Journal:  Mol Endocrinol       Date:  2013-04-16

3.  The androgen axis in recurrent prostate cancer.

Authors:  James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531
  3 in total
  2 in total

Review 1.  Revisiting nomenclature for the description of prostate cancer androgen-responsiveness.

Authors:  Hannelore V Heemers; James L Mohler
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

2.  Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.

Authors:  Lydia Livas; Sumati Hasani; Natasha Kyprianou
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.